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Because nuclear-transplanted embryonic stem 
(ES) cells and induced pluripotent stem (iPS) 
cells share their nuclear DNA background with 
their nuclear donors, they are considered to be 
promising cellular systems for generating tissues 
that will not be rejected upon transplantation 
into a host (French et al., 2006; Byrne et al., 
2007; Takahashi et al., 2007; Yu et al., 2007; 
Park et al., 2008). However, these cells are 
not complete clones of the hosts with respect   
to their mitochondrial DNA (mtDNA). The 
mtDNA in nuclear-transplanted ES cells is de-
rived from the donors of the ES cells and thus 
differs from the mtDNA of their nuclear do-
nors (Evans et al., 1999; Hall et al., 2006). Even 
in the case of iPS cells, the mtDNA accumulates 
specific somatic mutations during aging of the 
donors. Mutations in mtDNA have been pro-
posed  to  be  associated  with  mitochondrial 
diseases, aging, tumor formation, and various 
age-associated disorders such as diabetes mellitus 
and Parkinson’s disease (Larsson and Clayton, 
1995; Wallace, 1999). Moreover, our recent 
studies (Ishikawa et al., 2008a,b) showed that 
mtDNA mutations that induce overproduction 
of reactive oxygen species (ROS) are responsi-
ble for the development of metastatic potential 
of some tumor cells. Some mtDNA polymor-
phisms  can  be  recognized  by  the  acquired   
immune system of the host (Loveland et al., 
1990). Thus, it is possible that the mtDNA in 
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Mitochondrial DNA (mtDNA) has been proposed to be involved in respiratory function, and 
mtDNA mutations have been associated with aging, tumors, and various disorders, but the 
effects of mtDNA imported into transplants from different individuals or aged subjects 
have been unclear. We examined this issue by generating trans-mitochondrial tumor cells 
and embryonic stem cells that shared the syngenic C57BL/6 (B6) strain–derived nuclear 
DNA background but possessed mtDNA derived from allogenic mouse strains. We demon-
strate that transplants with mtDNA from the NZB/B1NJ strain were rejected from the host 
B6 mice, not by the acquired immune system but by the innate immune system. This rejec-
tion was caused partly by NK cells and involved a MyD88-dependent pathway. These results 
introduce novel roles of mtDNA and innate immunity in tumor immunology and transplan-
tation medicine.
© 2010 Ishikawa et al.  This article is distributed under the terms of an Attri-
bution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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mtDNA from the C3H and NZB strains (Fig. S2 C) was not 
sufficient to induce lung metastasis.
We next examined the effects of allogenic mtDNA on 
the host–donor compatibility by inoculating the tumor cy-
brids under the back skin of the B6 mice (Fig. 1 B). There 
was a marked difference in the latency for tumor formation 
between P29mtB6 cybrids and the cybrids with allogenic 
mtDNA. Although P29mtB6 formed tumors within 10 d of 
the inoculation, P29mtC3H took >25 d to form tumors, and 
P29mtNZB did not form them at all. Considering the 99.98% 
identity between the B6 and C3H mtDNA sequences, it was 
conceivable that the longer latent period of P29mtC3H was 
caused by the 0.02% sequence difference between the B6 and 
C3H mtDNAs. Meanwhile, it is plausible that the greater di-
vergence between the NZB mtDNA and the B6 mtDNA 
(0.5% sequence difference between B6 and NZB) prevented 
tumor formation by the P29mtNZB cybrid. Moreover, the 
injection of a mixture of P29mtB6 and P29mtNZB resulted 
in primary tumors (Fig. 1 B, left) that consisted exclusively of 
P29mtB6 cells (Fig. 1 B, right). The slower tumor growth of 
the  P29mtB6  and  P29mtNZB  mixture  than  of  P29mtB6 
alone may be attributable to the P29mtB6 and P29mtNZB 
mixture containing only half as many P29mtB6 cells as the 
P29mtB6-only inoculant. These results strongly suggest that the 
cybrids possessing allogenic mtDNA were selectively hindered 
from forming tumors in the host B6 mice.
To address the mechanism of this selective suppression of 
tumor formation, we performed the same experiment using 
B6mtNZB congenic mice as the hosts. They share the B6 
nuclear DNA background but possess mtDNA that is exclu-
sive to the NZB strain mice. When the B6mtNZB mice with 
NZB mtDNA were used as the hosts, P29mtNZB formed 
tumors, but P29mtB6 and P29mtC3H did not (Fig. 1 C), 
suggesting the self-tolerance of cells with syngenic mtDNA. 
Probably, mtDNA polymorphism might elicit host immune 
responses to selectively suppress the growth of the tumor cy-
brids possessing allogenic mtDNA.
Determination of the immune systems that suppress  
tumor formation
Cytotoxic T cells (CD8+ T cells) recognize an amino acid 
change caused by the A2766G and T2767C mutations in 
the gene encoding ND1 (NADH dehydrogenase subunit 1) of 
NZB mtDNA (I6A) and kill lymphocytes containing the 
NZB mtDNA in vitro (Loveland et al., 1990). Therefore, 
the selective suppression of tumor formation by P29mtNZB 
in B6 mice (Fig. 1 B) could have been caused by the ac-
quired immune system, including CD8+ T cells. To test   
this possibility, we inoculated P29mtNZB into B6 2m/ 
mice, which lack CD8+ T cells because of a lack of MHC 
class I expression (Table S1). However, P29mtNZB did not 
form tumors in these mice (Fig. 2 A). The results were simi-
lar when we used the B6 Tap1/ mice, another MHC class 
I–deficient model (Fig. 2 A). P29mtNZB was also rejected 
in the B6 Ab/ mice, which are CD4+ T cell–deficient 
mice lacking MHC class II molecules (Fig. 2 B), and in the 
nuclear-transplanted ES cells and in iPS cells could influence 
mitochondrial respiratory function, tumor phenotypes, and 
the host–donor compatibility of the transplants differentiated 
from these cells.
RESULTS AND DISCUSSION
Isolation of the trans-mitochondrial tumor cells (tumor 
cybrids) with allogenic mtDNA
To examine the effects of mtDNA derived from allogenic 
strain mice on respiratory function, tumor phenotypes, and 
host–donor compatibility, we have to exclude the effects of 
nuclear DNA variations on these phenotypes. We resolved 
this problem by generating trans-mitochondrial tumor cells 
(tumor cybrids; see Materials and methods), which shared the 
C57BL/6 (B6) strain–derived nuclear DNA but possessed 
mtDNA polymorphisms (Bayona-Bafaluy et al., 2003) de-
rived from different allogenic strain mice. As nuclear DNA 
donors and mtDNA recipients, we used mouse mtDNA- 
less P29 cells (0P29 cells), which were isolated previously   
(Ishikawa et al., 2008a) from poorly metastatic Lewis lung 
carcinoma P29 cells derived from a B6 strain (Koshikawa and 
Takenaga, 2005).
The tumor cybrids were obtained by fusion of the 0P29 
cells with enucleated cells carrying mtDNA from the syn-
genic strain B6 or the allogenic strain C3H/An (C3H) or 
NZB/B1NJ (NZB; Fig. S1 A). The resultant tumor cybrids 
were  named  P29mtB6,  P29mtC3H,  and  P29mtNZB,  re-
spectively. Complete mtDNA replacement in the tumor cy-
brids was confirmed by restriction enzyme digestion of the 
PCR products (Fig. S2 A).
Effects of allogenic mtDNA on respiratory function, tumor 
phenotypes, and host–donor compatibility
First, we examined the effects of the allogenic mtDNA in the 
tumor cybrids on respiration and the production of ROS. 
We found no significant differences among the tumor cy-
brids in respiration complex activities, ATP contents, or O2 
consumption rates (Fig. S2 B), although a slight increase in 
the  amounts  of  ROS  was  observed  in  P29mtC3H  and 
P29mtNZB (Fig. S2 C), which is consistent with a previous 
study (Moreno-Loshuertos et al., 2006).
Our previous study (Ishikawa et al., 2008a) showed that 
ROS production confers metastatic potential in tumor cells. 
Therefore, we examined the effect of the augmented ROS 
production on experimental and spontaneous metastases by 
inoculating P29mtB6, P29mtC3H, and P29mtNZB into the 
tail vein and under the back skin of recipient B6 mice (Fig. 1 A). 
As a positive control, we used P29mtA11, which was gener-
ated previously by 0P29 cells with highly metastatic Lewis 
lung carcinoma A11 cells (Ishikawa et al., 2008a). It expressed 
highly metastatic potentials caused by mtDNA with a G13997A 
mutation, which is derived from A11 cells, and induced   
sufficient ROS overproduction required for inducing meta-
static potential (Ishikawa et al., 2008a). We found that   
only P29mtA11 formed lung nodules (Fig. 1 A), which sug-
gested that the increase in ROS production by the allogenic JEM VOL. 207, October 25, 2010  2299
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Involvement of NK cells and DCs in the suppression  
of tumor formation
Involvement of NK cells in the rejection of the tumor cybrids 
with allogenic mtDNA was confirmed by experiments in NKRed 
mice, which have a reduced number of NK cells (Fig. S3) as 
the result of i.p. injection of anti-NK1.1 antibody. Although 
tumor growth was very slow, P29mtNZB did form tumors 
in the B6 NKRed mice (Fig. 2 E). Similarly, P29mtB6 formed 
tumors in the B6mtNZB NKRed mice (Fig. 2 F). Further-
more, co-cultivation of B6-derived NK cells with the tumor 
cybrids in vitro showed that the NK cells were more cyto-
toxic to P29mtNZB than to P29mtB6 (Fig. 2 G). This cyto-
toxicity was significantly inhibited by the perforin inhibitor 
concanamycin A, but the anti-FasL antibody had no effect. 
These  observations  indicate  that  the  cytotoxicity  of  B6- 
derived NK cells to P29mtNZB was partly dependent on 
perforin but independent of the Fas-FasL system (Fig. 2 G). 
Although our data do not exclude possibilities other than di-
rect killing of the tumor cybrids by NK cells, they support 
the idea that preferential killing of P29mtNZB by B6 NK 
B6  recombination-activating  gene–deficient  (Rag2/)  mice   
(T cell– and B cell–deficient mice; Fig. 2 C). Thus, the ac-
quired immune system does not appear to be responsible for 
the rejection of the tumor cybrids with allogenic mtDNA 
(Fig. 1, B and C).
Surprisingly, the P29mtNZB cybrids could form tumors 
when used to inoculate B6 Rag2//c/ mice, which are 
deficient in both RAG2 and the common cytokine recep-
tor c (Fig. 2 D). However, P29mtNZB recovered from 
the tumor masses formed in the B6 Rag2//c/ mice 
did not make tumors in the B6 mice. This finding ex-
cluded the possibility that some revertants in the injected 
P29mtNZB population selectively grew in the B6 Rag2// 
c/ mice. The B6 Rag2//c/ mice are severe com-
bined  immunodeficiency  models  that  have  macrophages 
and granulocytes but no T cells, B cells, NK cells, or func-
tional DCs (Table S1). Thus, the innate immune system, 
including NK cells and DCs, and not the acquired immune 
system, is responsible for the rejection of P29mtNZB in   
B6 mice.
Figure 1.  Effects of allogenic mtDNA on the expression of tumor phenotypes. (A) Experimental (left) and spontaneous (right) lung metastasis 
phenotypes of the tumor cybrids. Metastatic phenotypes were examined by inoculation of the tumor cybrids containing allogenic mtDNA derived from 
different strain mice into the tail veins or under the skin of B6 mice. (B) Tumor formation phenotype of the tumor cybrids. Total numbers of 5 × 106 tumor 
cybrids were inoculated under the skin of B6 mice (left). A mixture of P29mtB6 (2.5 × 106) and P29mtNZB (2.5 × 106) was also inoculated (left) to confirm 
the selective tumor formation of P29mtB6 (n = 6 for each group). Data are representative of two independent experiments (*, P < 0.005; **, P < 0.0005). 
Restriction enzyme (SphI) digestions of PCR products were performed to identify the mtDNA genotypes (right). After the digestion, NZB mtDNA  
produced 143- and 31-bp fragments, whereas B6 mtDNA remained 174-bp PCR products. Mixed cybrids represent a simple mixture of P29mtB6 and 
P29mtNZB. Tumors represent primary tumors formed by inoculation of the mixed cybrids. (A and B) Error bars represent SD. (C) Tumor formation  
phenotype of the tumor cybrids inoculated under the skin of the B6mtNZB mice. Data represent the mean ± SD (n = 6). Similar results were obtained in 
two independent experiments.2300 Innate immunity targets allogenic mtDNA | Ishikawa et al.
Figure 2.  Determination of the immune system that suppresses tumor formation of the tumor cybrids containing allogenic mtDNA.  
(A–F and H) The tumor cybrids were inoculated under the skin of B6 2m/ and B6 Tap1/ mice (A), B6 Ab/ mice (B), B6 Rag2/ mice (C), B6 
Rag2//c/ mice (D), B6 NKRed mice (E), B6mtNZB NKRed mice (F), and B6 Myd88/ and B6 Myd88//NKRed mice (H) to study the involvement of the 
immune system and immune cells in the suppression of tumor formation (n = 6). Similar results were obtained in two independent experiments. Error 
bars represent SD. (G) Contribution of perforin but not FasL in preferential killing of P29mtNZB by NK cells derived from B6 Rag2/ mice. Cytotoxic assay 
of B6 Rag2/ splenocytes that had been stimulated with poly I:C in vivo for 20 h was tested against P29mtB6 or P29mtNZB at the indicated E/T ratios. 
An 8-h 51Cr releasing assay was performed in the presence or absence of 20 nM concanamycin A or 10 µg/ml anti-FasL antibody. In all experiments, spon-
taneous 51Cr release from the P29 cybrids was <15%. Data represent the mean ± SD of triplicate samples. Similar results were obtained in two indepen-
dent experiments (*, P < 0.0005; **, P < 0.0001).JEM VOL. 207, October 25, 2010  2301
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growth was very slow, P29mtNZB did form tumors 
in the B6 Myd88/ mice (Fig. 2 H). Thus, MyD88-
associated innate receptors such as TLRs played an 
important role in the rejection of P29mtNZB. We 
next used B6 Myd88/ NKRed mice, which simulta-
neously lacked most NK cells and most functional TLRs, 
and found significant tumor growth of P29mtNZB 
(Fig. 2 H). These observations, together with the   
results shown in Fig. 2 D, suggested that NK cells and 
other innate immune cells that can mediate MyD88-
dependent innate immune responses such as DCs are 
involved in suppressing the growth of the tumor   
cybrids containing allogenic mtDNA.
The involvement of the innate immune system in 
suppressing the growth of tumor cybrids containing 
allogenic mtDNA was supported by immunohisto-
chemical analyses of the cell clusters that formed un-
der the skin of the B6 mice 4–12 d after the inoculation 
of P29mtB6 and P29mtNZB (Fig. 3 A). An increased 
infiltration of mononuclear cells, including DCs, into 
the cell clusters of P29mtNZB was observed 4 d after 
inoculation. Quantitative flow cytometric analyses of 
the infiltrated cells (Fig. 3 B) indicated that the infil-
tration of DCs into the P29mtNZB clusters was fol-
lowed by an accumulation of NK cells on day 12. On the 
contrary, the transcription of IL-12p40, which is produced 
by DCs and encodes a product important for NK cell activa-
tion (Yu et al., 2001; Miller et al., 2003), was detectable in 
both P29mtNZB and P29mtB6 cell clusters (Fig. 3 C), suggest-
ing that the s.c. inoculation with the cybrids enhanced IL-12 
production independent of the mtDNA allogenicity. The in-
jection of the cybrids might cause the release of mitochon-
dria-derived  damage-associated  molecular  patterns,  which 
induce damage-dependent inflammation (Rabiet, et al. 2005, 
cells is partly involved in the suppression of tumor formation 
of P29mtNZB in B6 mice.
The slow growth of tumor cybrids with allogenic mtDNA 
in the NKRed mice (Fig. 2, E and F) could be caused by the 
involvement of innate immune cells other than NK cells in 
the rejection of the tumor cybrids. We examined this possi-
bility  by  inoculating  P29mtNZB  into  the  B6  Myd88/ 
mice, which lack a functional innate immune system because 
they do not have functional Toll-like receptors (TLRs) ex-
cept for TLR3 (Adachi et al., 1998). Although the tumor 
Figure 3.  Infiltration of NK cells and DCs into cell clusters 
formed by inoculation of the tumor cybrids into the B6 
mice. (A) Identification by histochemical analysis of the mono-
nuclear cells that infiltrated into cell clusters. P29mtB6 and 
P29mtNZB formed small cell clusters on day 4 after inoculation 
into B6 mice. P29mtB6 showed an increase in cluster size from 
day 4–12, but P29mtNZB showed a decrease in cluster size. H&E 
staining showed preferential infiltration of the mononuclear 
cells into cell clusters of P29mtNZB. Photographs of higher 
magnification of boxed areas are shown below. Immunohisto-
chemical analyses showed preferential infiltration of CD11c+ DCs 
into cell clusters of P29mtNZB at day 4. Bars: (gray) 5 mm; 
(black) 20 µm. (B) Quantitative estimation of the NK cells and 
DCs that infiltrated into cell clusters by flow cytometric analysis 
using CD45+ lymphocytes isolated from the cell clusters. CD11c, 
B220, CD3, and NK1.1 are lineage-specific markers for DCs, B 
cells, T cells, and NK cells, respectively. The red boxes in the top 
and bottom panels indicate NK cells (CD3 and NK1.1+) and DCs 
(CD11c+ and B220), respectively. (C) Transcription of cytokines 
in cell clusters. Total RNA was prepared from cell clusters, and 
RT-PCR analyses were performed. Similar results were obtained 
in two independent experiments.2302 Innate immunity targets allogenic mtDNA | Ishikawa et al.
whereas ESmtNZB but not ESmtB6 formed tumors in the 
B6mtNZB mice (Fig. 4 C). Moreover, ESmtNZB did not 
form tumors in the B6 2m/ mice (Fig. 4 D) but did form 
tumors in the B6 NKRed mice (Fig. 4 E), which suggests the 
involvement of NK cells in the rejection of the ES cybrids. 
Therefore, even when tissues are reconstructed from stem 
cells, they could be rejected if they possess mtDNA with mu-
tations that trigger the innate immune system.
Using  our  complete  mtDNA  replacement  technology 
(Ishikawa et al., 2008a,b), this study uncovered novel roles   
of mtDNA and innate immunity in tumor suppression. We 
showed that the host innate immune system cannot recog-
nize tumor and ES cells carrying a syngenic nuclear DNA 
and a syngenic mtDNA but can recognize tumor and ES cells 
carrying a syngenic nuclear DNA and an allogenic mtDNA 
without priming. Although the acquired immune system, in-
cluding effector CD8+ T cells, can be elicited in the case of 
repeated immunization (Loveland et al., 1990), innate recog-
nition of tumor cells and ES cells with allogenic mtDNA 
should be a focus of our attention in the context of interac-
tions between the hosts and tumor cells and between the 
hosts and grafts differentiated from somatic cells. In fact, graft 
rejection was reported in the renal transplants with allo-
genic mtDNA of swine (Hanekamp et al., 2009). Even the 
mtDNA of iPS cells might accumu-
late certain somatic mutations during   
the aging of the donor, and it could   
be allogenic mtDNA that influences 
host–donor compatibility.
Many questions remain about the 
mechanism of the innate recognition 
of  the  cells  with  allogenic  mtDNA. 
For example, it is not known which 
products of the allogenic mtDNA are 
responsible  for  its  innate  recognition   
or which molecules sense the alloge-
nicity of the mtDNA. Our experi-
ments of inoculation of the mixture of 
P29mtB6 and P29mtNZB demonstrated 
selective  elimination  of  P29mtNZB 
from the same cell clusters in B6 mice 
(Fig. 1 B), strongly suggesting that the 
P29mtNZB cybrids were eliminated 
Zhang, et al., 2010). Because other NK-activating cytokines 
such as IL-18 and IL-15 also appeared to be transcribed (Fig. 3 C), 
it is conceivable that inoculation of the tumor cybrids in-
duces nonspecific activation of innate immune cells such as 
DCs and macrophages, resulting in the activation of NK cells, 
which can specifically recognize and exclude the tumor cy-
brids with allogenic mtDNA.
Rejection of the transplanted ES cybrids with allogenic 
mtDNA by the innate immune system
We were also interested in examining whether similar rejec-
tion can be observed when nontumor ES cybrids carrying 
nuclear DNA from the B6 mice and mtDNA from the NZB 
mice were transplanted into the B6 mice. This issue would 
be very important when we consider transplantation of the 
tissues differentiated from nuclear-transferred ES cells or iPS 
cells possessing such mtDNA that induce the innate immune 
system. To this end, we isolated the ES cybrids (ESmtB6 and 
ESmtNZB) sharing nuclear DNA with the B6 strain mice 
but  possessing  mtDNA  from  the  B6  and  NZB  strain   
mice, respectively, by using B6-derived B6G-2 ES cells   
(Shimizukawa et al., 2005) as the nuclear DNA donors and 
mtDNA recipients (Fig. 4 A and Fig. S1 B). ESmtB6 but 
not ESmtNZB formed tumors in the B6 mice (Fig. 4 B), 
Figure 4.  Rejection of the transplanted 
ES cybrids containing allogenic mtDNA.  
(A) Identification of the mtDNA genotypes of 
the ES cybrids. B6 and NZB represent mtDNAs 
from B6 and NZB mice, respectively.  
(B–E) Examination of tumor formation of the 
ES cybrids by their inoculation into B6 mice 
(B), B6mtNZB mice (C), B6 2m/ mice (D), 
and B6 NKRed mice (E). Similar results were 
obtained in two independent experiments. 
Error bars represent SD.JEM VOL. 207, October 25, 2010  2303
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digested by Tth111I. For recognition of the NZB mtDNA, the nucleotide 
sequences from nucleotide position 2736 to 2765 (5-ATCCTCTCCCTA-
ATAGTGTTCTTTATgcAT-3 [lowercase indicate mismatch sites]) and 
nucleotide  position  2909  to  2889  (5-TATGGCGTCTGCAAATGG-
TTG-3) were used as primers, and the PCR products were digested by SphI.
Biochemical measurement of respiratory enzyme activities. Cells in 
log-phase growth were harvested, and the mitochondrial respiratory func-
tion was examined as described previously (Miyabayashi et al., 1989).
Mouse strains and crosses. Mice of the inbred strain B6 and NZB were 
obtained from CLEA Japan, Inc. and the National Institute of Genetics   
(Shizuoka, Japan), respectively. Using these strains, we obtained B6mtNZB 
mice by repeated backcrosses (female progenies [NZB female × B6 male] × 
B6 male) >20 times. NZB mtDNA provided normal respiratory function in 
the cybrids with B6 nuclear DNA (Fig. S2 B). Thus, they possess intact nu-
clear genome from the inbred B6 strain and intact mitochondrial genome 
from NZB strain. The immunodeficient 2m/, Ab/, and Rag2/ 
mice were obtained from Taconic. The Tap1/ mice were purchased from 
The Jackson Laboratory. The Rag2//c/ mice were provided by   
S. Koyasu and S. Nagai (Keio University School of Medicine, Shinju-ku, 
Tokyo, Japan). The Myd88/ mice were obtained from T. Kaisho (RIKEN 
Research Center for Allergy and Immunology, Tsurumi-ku, Yokohama 
City, Japan). All of these immunodeficient mice share B6 nuclear DNA 
background. To obtain NKRed, B6mtNZB NKRed, and Myd88/ NKRed 
mice, each mouse received repeated i.p. injection of anti-NK1.1 antibody 
(clone PK136; Acris Antibodies GmbH) from 1 wk after the birth (10 µg/wk 
for 1 wk old, 20 µg/wk for 2 wk old, 50 µg/wk for 3 and 4 wk old, and 100 
µg/wk for >5 wk old). Experiments were performed according to the guide-
lines for animal use and experimentation of the University of Tsukuba and 
the International Medical Center of Japan.
Assays of metastatic potentials and tumor formation. For testing ex-
perimental metastasis, 5 × 105 cells in 100 µl PBS were injected into the tail 
vein of 6-wk-old male B6 mice. The mice were sacrificed 18 d later, and their 
lungs were removed, and then parietal nodules were counted. In an experi-
mental metastasis model, cells are intravenously inoculated. Thus, this model 
bypasses the initial steps of the metastatic cascade, including primary tumor 
growth, invasion, and intravasation, and has been termed experimental metas-
tasis to differentiate it from spontaneous metastasis (Criscuoli, et al. 2005). To 
examine spontaneous metastasis and tumor formation, 5 × 106 cells in 100 µl 
PBS were injected s.c. into the back of 6-wk-old male mice. The recipient 
mice were sacrificed when the tumor volume reached 5,000 mm3, and their 
lungs were removed, and then parietal nodules were counted. In a spontane-
ous metastasis model, all of the steps of the metastatic cascade from primary   
tumor growth to secondary growth in distant organs were traversed.
Histochemical analyses. Removed cell clusters were either fixed in 10% 
formalin for hematoxylin and eosin (H&E) staining or immediately frozen in 
the Tissue-Tek OCT compound (Sakura Finetek) for immunohistochemical 
analyses. Frozen cell clusters were sliced into 10-µm-thick cryosections and 
fixed in cold acetone. Anti-CD11c antibodies (BD) were used as primary 
antibodies and then visualized by the HRP Detection kit (BD).
Cytotoxic assay. A 51Cr release assay was performed to examine cytotoxic 
activity of cells (Mazumder et al., 1983). For preparation of polyinosinic:
polycytidylic acid (poly I:C)–activated NK cells, 100 µg of poly I:C (P-0913; 
Sigma-Aldrich) was i.p. injected into B6 Rag2/ mice, and spleen cells 
were  isolated  20  h  after  the  injection.  The  target  cells  (P29mtB6  and 
P29mtNZB) were labeled with 51Cr (3,700 KBq/106 cells) for 30 min at 
37°C and used as target cells in the killer assay. After removing the excess 
51Cr by washing cells with the complete medium, the target cells were plated 
in V-bottom 96-well plates at 104 cells/well and mixed with effector cells in 
a final volume of 200 µl. After 8 h of incubation, cell-free supernatants were 
collected, and radio activities were measured in a gamma counter. In some 
and the P29mtB6 cybrids persisted in the same cytokine envi-
ronment. Thus, the immunological discrimination of mtDNA 
allogenicity by effector cells is an important mechanism for 
eliminating foreign cells. Collectively, with the findings that 
B6-derived NK cells were more cytotoxic to P29mtNZB than 
to P29mtB6 (Fig. 2 G) and that NK cells were detectable in 
the cell clusters that formed after cybrid inoculation (Fig. 3 B), 
NK cells seem to be important for recognizing mtDNA allo-
genicity. Thus, how the NK cells recognize cells with allogenic 
mtDNA is another critical question. It is also important to 
elucidate whether allogenic mtDNA recognition also occurs 
in vivo under physiological conditions. Although the precise 
mechanism by which the innate immune system, including 
NK  cells  and  DCs,  recognizes  cells  containing  allogenic 
mtDNA needs to be further investigated, this study provides 
potentially important information for the fields of tumor im-
munology and transplantation medicine.
MATERIALS AND METHODS
Cell lines and cell culture. Low metastatic P29 cells are originated from 
B6 mouse–derived Lewis lung carcinomas. B6G-2 ES cells are B6 mouse–
derived ES cells obtained from the RIKEN BioResource Center (Shimizukawa 
et al., 2005). All of the cells except for ES cells and their cybrids were grown 
in normal medium (DME + 1 mM sodium pyruvate + 50 µg/ml uridine + 
10% FBS). B6G-2 ES cells and their cybrids were grown in ES medium 
(high glucose DME + 1 mM sodium pyruvate + 50 µg/ml uridine + 15% 
FBS + 0.1 mM of nonessential amino acid + 0.1 mM 2-mercaptoethanol + 
1,000 U/ml leukemia inhibitory factor [Invitrogen]).
Isolation of the cybrids. As nuclear donors and mtDNA recipients for iso-
lation of the tumor cybrids, we used 0P29 cells (Fig. S1 A). We also used ES 
cells pretreated with 1 µg/ml R6G (rhodamine 6G) for 48 h to eliminate their 
endogenous mitochondria and mtDNA as nuclear donors and mtDNA recip-
ients for isolation of the ES cybrids (Fig. S1 B). As mtDNA donors, we used 
B82 cybrids (B82mtB6, B82mtC3H, and B82mtNZB; see Fig. S1) because 
they express HAT-sensitive phenotypes and can be excluded in the presence 
of HAT (Ishikawa et al., 2008a). Moreover, B82 cybrids share the C3H strain 
nuclear DNA background and thus can exclude the possibility of participation 
of other cytoplasmic materials than mtDNA and its products in the rejection 
of the cybrids. B82mtB6, B82mtC3H, and B82mtNZB cybrids were isolated 
by the fusion of the 0B82 cells with the platelets from B6, B6mtC3H, and 
B6mtNZB mice, which possess the B6 strain nuclear DNA background but 
possess mtDNA from B6, C3H, and NZB strain mice, respectively. Enucle-
ation of the B82 cybrids was performed by their pretreatment with 10 µg/ml 
cytochalasin B for 10 min and centrifugation at 22,500 g for 30 min. Resultant 
cytoplasts were fused with 0P29 cells or with R6G-pretreated B6G-2 ES 
cells by polyethylene glycol. Unfused 0P29 cells or R6G-pretreated ES cells 
failed to grow as a result of the absence of mtDNA or mitochondria, and un-
enucleated B82 cybrids failed to grow by the HAT selection.
Genotyping of mtDNA. The mtDNA genotypes of the isolated cybrids 
were confirmed by RFLP analysis of the PCR products because there are 
strain-specific polymorphisms: the C9461T mutation for B6 mtDNA, the 
G9348A mutation for C3H mtDNA, and the A2766G/T2767C mutations 
for NZB mtDNA. To identify the B6 mtDNA, the nucleotide sequences 
from  nucleotide  position  9434  to  9460  (5-TTCTGAATAAACC-
CAGAAGAGAGTgAT-3  [lowercase  indicates  the  mismatch  site])  and   
nucleotide position 9,584 to 9,558 (5-GTCGAATCCGCATTCATATG-
GATTTGC-3) were used as primers, and the PCR products were digested 
by BclI. To distinguish the C3H mtDNA, the nucleopeptide sequences 
from nucleotide position 9316 to 9335 (5-CCGCAGCATGATACTG-
ACAT-3)  and  nucleotide  position  9534  to  9516  (5-GGGGGAGT-
CAGAATGCAAC-3) were used as primers, and the PCR products were 2304 Innate immunity targets allogenic mtDNA | Ishikawa et al.
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experiments, the effector cells were pretreated with 20 nM concanamycin A 
(Wako Pure Chemicals) for 2 h to inactivate perforin (Kayagaki et al., 1999), 
or anti-mFasL monoclonal antibody (MFL2) was added to a final concentra-
tion of 10 µg/ml at the start of the cytotoxic assay.
RT-PCR analyses. Total RNA was prepared from cell clusters, and RT-PCR 
analyses were performed using the following primers: 5-CCACTCACAT-
CTGCTGCTCCACAAG-3  (sense)  and  5-ACTTCTCATAGTCCCT-
TTGGTCCAG-3  (antisense)  for  IL-12p40,  5-CATCCATCTCGTGC-
TACTTG-3 (sense) and 5-ACATCTATCCAGTTGGCCTC-3 (antisense) 
for IL-15, 5-GGCCTGACATCTTCTGCAAC-3 (sense) and 5-GAGTC-
TTCTGACATGGCAGC-3 (antisense) for IL-18, and 5-TTCTTTG-
CAGCTCCTTCGTTG-3 (sense) and 5-GATGGCTACGTACATGG-
CTGG-3 (antisense) for -actin.
Statistical analysis. The data were analyzed with a Student’s t test. All   
values are the mean ± SD, and values with P < 0.05 were considered 
significant.
Online supplemental material. Fig. S1 is the scheme explaining how 
to generate the mtDNA-exchanged cybrids. Fig. S2 shows the mtDNA 
genotypes and respiratory phenotypes of the cybrids. Fig. S3 shows effi-
cient  depletion  of  NK  cells  by  injecting  anti-NK1.1  antibody  PK136. 
Table SI explains the genetic and immune characteristics of the recipient   
mice. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20092296/DC1.
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